Semaglutide and cardiovascular outcomes by frailty status in SELECT (post hoc analysis)

Ostrominski JW et al.

1. 01

   Lower MACE, all-cause hospitalization and all-cause mortality with semaglutide across frailty strata (as described; HRs not verified)

2. 02

   Fewer discontinuations for adverse events among more frail participants

3. 03

   Frailty index more likely to improve and less likely to worsen on semaglutide vs placebo

4. 04

   About two-thirds of participants were frail by index; ~3/4 male; mean age ~62

Study Design

Post hoc analysis of RCT

Sample Size

Not reported

Study Duration

Not reported

Methodology

Post hoc secondary analysis of SELECT (randomized, double-blind, placebo-controlled); 31-item frailty index strata (not frail / more frail / most frail)

Limitations

Post hoc and hypothesis-generating. Mean age ~62 and predominantly male; frailty captured by a deficit-accumulation index rather than physical performance, so strength/sarcopenia outcomes are not established. SELECT excluded type 2 diabetes, class IV heart failure and end-stage kidney disease/dialysis. Publication date approximate (September 2026 per JAMA Medical News). HRs not verified.